MedPath

DupuytrEn Treatment EffeCtiveness Trial (DETECT)

Phase 3
Recruiting
Conditions
Dupuytren's contracture
Registration Number
2024-515110-40-00
Lead Sponsor
Pirkanmaan hyvinvointialue, Pirkanmaan hyvinvointialue
Brief Summary

To determine, which treatment strategy 1) primary PNF followed by surgical LF in patients who do not respond to PNF, 2) primary CCH followed by surgical LF in patients who do not respond to CCH or 3) LF as the primary (and secondary) treatment modality is the most efficacious and cost-effective in treating DC in 5-year follow-up.

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing, recruiting
Sex
Not specified
Target Recruitment
50
Inclusion Criteria
  1. patients with at least 20° combined extension deficit in metacarpophalangeal joint (MP) and/or proximal interphalangeal joint (PIP) in finger/fingers II-V 2) age > 18 years 3) palpable cord 4) provision of informed consent 5) ability to fill the Finnish versions of questionnaires
Exclusion Criteria
  1. recurrent contracture in the finger to be treated 2) neurologic condition causing the loss of function of the finger to be treated 3) contraindication for collagenase clostridium histolyticym (Xiapex/Xiaflex ®) 4) pregnant or breast feeding 5) TPED > 135° (Tubiana stage 472) in finger to be treated 6) rheumatoid arthritis 7) previous fracture in finger to be treated, which affects range of motion of MP or PIP joint 8) age > 80 years

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Success at five years

Success at five years

Secondary Outcome Measures
NameTimeMethod

Related Research Topics

Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.

What molecular mechanisms underlie Dupuytren's contracture and how do collagenase clostridium histolyticum, percutaneous needle fasciotomy, and limited fasciectomy modulate these pathways?
How does collagenase clostridium histolyticum compare to percutaneous needle fasciotomy and limited fasciectomy in terms of efficacy and cost-effectiveness for mild to moderate Dupuytren's contracture?
What biomarkers are associated with favorable outcomes in Dupuytren's contracture patients undergoing collagenase clostridium histolyticum, percutaneous needle fasciotomy, or limited fasciectomy treatments?
What are the known or potential adverse events associated with collagenase clostridium histolyticum, percutaneous needle fasciotomy, and limited fasciectomy in Dupuytren's contracture management?
Are there related compounds or combination approaches that enhance the therapeutic outcomes of collagenase clostridium histolyticum, percutaneous needle fasciotomy, or limited fasciectomy in Dupuytren's contracture treatment?

Trial Locations

Locations (6)

Central Finland Hospital District Central Finland Hospital Nova

🇫🇮

Jyvaskyla, Finland

HUS-Yhtymae

🇫🇮

Helsinki, Finland

Turku University Hospital

🇫🇮

Turku, Finland

Oulu University Hospital

🇫🇮

Oulu, Finland

Tampere University Hospital

🇫🇮

Tampere, Finland

Kuopio University Hospital

🇫🇮

Kuopio, Finland

Central Finland Hospital District Central Finland Hospital Nova
🇫🇮Jyvaskyla, Finland
Teemu Karjalainen
Site contact
+358142691811
teemu.karjalainen@hyvaks.fi

Related Trials

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.